—
C+
C+ The full Closelook — membership. Open the C+ overview

Genmab AS (GMAB) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Genmab AS

GMAB in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development.
Where it sits in the stack
Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line.
Who it is priced against
Closelook's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.
Why Closelook tracks it
It carries a Closelook score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.
What the diary watches
Whether new approvals or expanded partner deals convert its pipeline into steadier royalty income, since much of its revenue still depends on collaborations with other drugmakers.

Genmab AS (GMAB) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GMAB, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GMAB on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Genmab AS (GMAB)?

Genmab AS trades as GMAB on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is GMAB in a Closelook index?

Not currently — Genmab AS is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does GMAB trade against its moving averages?

Uptrend stack intact: Trades +10.6% vs the 50-day and +17.9% vs the 200-day average, 1.9% below the 52-week high and +47.1% off the 52-week low; a golden cross printed 17 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Genmab AS do?

Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms. Its pipeline includes further antibody candidates aimed at solid tumours, leukaemia and other conditions, still in various stages of development. Closelook's peer group places it with other scored Healthcare names in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names AstraZeneca as a comparable oncology-antibody developer.

Where does Genmab AS sit in the AI build-out?

Genmab carries no seat in our index; it belongs to the Healthcare sector sleeve of the diary's US universe, where its business rests on royalties and shared revenue from approved antibody therapies rather than on any single owned product line. It carries a Closelook score with momentum as its strongest module and valuation as its weakest; it holds no index seat and has not yet appeared in the diary's quoted editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for GMAB, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.